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Engineering Silk Fibroin-Based Nerve Conduit with
Neurotrophic Factors for Proximal Protection after
Peripheral Nerve Injury
Cristiana R. Carvalho, Wei Chang, Joana Silva-Correia, Rui L. Reis, Joaquim M. Oliveira,*
and Joachim Kohn
Artificial nerve conduits capable of adequately releasing neurotrophic factors
are extensively studied to bridge nerve defects. However, the lack of
neurotrophic factors in the proximal area and their visible effects in axonal
retrograde transport following nerve injury is one of the factors causing an
incomplete nerve regeneration. Herein, an advanced conduit made of silk
fibroin is produced, which can incorporate growth factors and promote an
effective regeneration after injury. For that, enzymatically crosslinked silk
fibroin-based conduits are developed to be used as a platform for the
controlled delivery of neurotrophic factors. Nerve growth factor and glial-cell
line derived neurotrophic factor (GDNF) are incorporated using two different
methodologies: i) crosslinking and ii) absorption method. The release profile
is measured by ELISA technique. The bioactivity of the neurotrophic factors is
evaluated in vitro by using primary dorsal root ganglia. When implanted in a
10 mm sciatic nerve defect in rats, GDNF-loaded silk fibroin conduits reveal
retrograde neuroprotection as compared to autografts and plain silk fibroin
conduit. Therefore, the novel design presents a substantial improvement of
retrograde trafficking, neurons’ protection, and motor nerve reinnervation.
1. Introduction
Peripheral nerve injuries (PNIs) are one of the most impor-
tant burdens in public healthcare systems worldwide. They are
considered intractable and a common disease with a high and
gradually increasing incidence over the past decades.[1] When
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surgically repairing PNIs, autologous nerve
graft is the current gold standard option
for bridging gaps that cannot be repaired
by direct suturing. Despite that, the au-
tograft is often associated with increased
morbidity, painful neuroma formation, and
inappropriate match of nerves.[2] To solve
some of the problems related to biolog-
ical grafts, artificial nerve guidance con-
duits (NGCs) have been developed as an al-
ternative strategy.[2] The properties of the
biopolymer used to engineer NGCs and the
features of the final conduit itself, such as
pore size and degradation, play a crucial
role in the nerve regeneration efficiency.
The biomaterial must be biocompatible and
support cellular growth, proliferation, and
migration.[3] Furthermore, NGCs must al-
low the passage of nutrients and oxygen, but
at the same time, inhibit the infiltration of
fibroblasts, which may form scar tissue at
the injury site.[4] Mechanical properties that
support nerve regeneration and flexibility
are also a prerequisite.[5] The previously developed silk-fibroin
(SF) conduits presented several advantages and overcame all
these problems, showing features such as kinking resistance-
ability and suturability.[3] Furthermore, silk-fibroin has had an
important role in terms of peripheral nerve regeneration (PNR)
over the last decades, and many successful strategies have been
developed to address PNR hurdles.[6] Being an inexpensive and
natural occurring fibrous protein, this FDA-approved biomate-
rial possesses adequate physicochemical as well as mechanical
properties for scaffolds production. Being an extremely versa-
tile and biocompatible material, several groups published their
experimental work, claiming it is an almost perfect biomaterial
for PNR.[7] Additionally, the process utilized in this experimental
work contains only natural, biological and nontoxic components.
Also, due to the natural silk properties, NTFs can be slowly re-
leased, showing very impressive long-term release.
However, even with the efforts and advances in the tissue en-
gineering (TE) field and the fact that peripheral nervous system
(PNS) has an intrinsic capacity to regenerate,[8] poor outcomes
are still a problem. They are mainly related to: I) death of pri-
mary motor and sensory neurons; II) absence of fiber regenera-
tion over the gap area, and III) target-organ incomplete reinner-
vation, limiting the full recovery of the patients at a functional
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and sensory level.[9] In fact, even when injured nerves are surgi-
cally restored in the optimal timeframe after the injury, the pe-
riod that axons take to regenerate is too extended, resulting in
the lack of contact between neurons and target organs. The con-
sequence is a state of chronic axotomy and end targets become
chronically denervated.[10] Such problem is not solved by the use
of simple hollow NGCs, that are FDA-approved and used exten-
sively in the clinics, but only provide regenerating nerves with
poor guidance and protection.[11] Several strategies have been
used to enhance functional and sensory recovery, aiming to in-
crease the number of suitable axons which correctly reach their
targets. In this sense, one of the most promising and prominent
possibilities to improve nerve regeneration is the inclusion of
neurotrophic factors (NTFs) in the NGCs. NTFs are endogenous
proteins capable of binding to cell receptors with the purpose of
modulating and directing cellular activities.[10] In relation to the
PNS, NTFs are able to promote neuronal survival, axonal regen-
eration and Schwann cells’ migration. Furthermore, it has been
reported that NTFs have a very good efficiency in enhancing not
only neurogenesis when applied concomitantly with scaffolds,
but also angiogenesis.[12]
With distinctive properties and functions, nerve growth fac-
tor (NGF) and glial cell line-derived neurotrophic factor (GDNF)
were used. Briefly, NGF promotes survival and axonal outgrowth
of sensory neurons both in vitro and in vivo,[13] and has been
proved to promote early axonal regeneration. However, the role
of NGF in the recovery of motor neuron function is restricted.[14]
On the other hand, GDNF is one of the most protective fac-
tors for motor neurons and is abundantly expressed by skeletal
muscle.[15] Nevertheless, it has also marked activity on sensory
neurons. Acting through different intrinsic mechanisms and dif-
ferent pathways, both NTFs will have various effects on neurons
and respective neurites, such as neurite elongation or density
increase. In the case of NGF, the trkA receptor is a 140 kDa
glycoprotein which binds NGF. The NGF-activated trkA recep-
tor undergoes dimerization and autophosphorylation at several
tyrosine residues that selectively trigger activity in several in-
tracellular signaling pathways, having direct action on sensory
neurons.[16] The GDNF, a neuronal survival factor, binds its core-
ceptor GDNF family receptor alpha1 (GFR alpha 1) and signals
through the receptor tyrosine kinase RET, showing its effects on
both sensory and motor neurons. These were the NTFs chosen
for this experimental work, due to their distinctive properties.
In addition to the selection of NTFs, it is recognized that the se-
lection of a suitable delivery method for these molecules is crucial
for an effective regenerative potential. The inclusion and conse-
quent deliver of growth promoting biological molecules can be
achieved by several ways, accounting for many different and ad-
justable delivery systems.[10] When considering the delivery of
NTFs from the conduit wall, methods such as conjugation,[17]
adsorption,[18] and physical entrapment in the wall[19] are among
the most used methods. Regardless of the delivery method, gen-
eral complications related to loss of bioactivity, initial burst re-
lease or too low daily dose must be avoided in order to have a
beneficial effect on nerve regeneration.[10]
Optimized delivery methods for NTFs eluted from SF conduits
described in the literature are solely based in the simple blend-
ing of NTFs in SF solution without further entrapment or elec-
trospinning technique.[6,20]
In this work, we have tested two methods: i) crosslinking and
ii) adsorption, and compared their efficacy for retention and con-
trolled delivery of GDNF or NGF. The methods are based on and
interrelated with the SF NGC production method. For such, a
new patented enzymatically crosslinked SF (eSF) conduit previ-
ously developed by our group was used.[3] The crosslinking pro-
cess utilizes tyrosine groups from the SF structure to form a
hydrogel. Therefore, we hypothesized that during crosslinking,
the NTFs would be trapped in a more complex and tighter SF
matrix,[3] creating a more appropriate condition for sustained re-
lease.
Such method was compared to the absorbing process, where
the eSF conduits are immersed in a NTFs solution, in which,
processes like absorption and adsorption were expected to oc-
cur. Due to the porosity of the conduit and its high surface-to-
volume ratio for solution penetration, we could envision that the
NTFs would be highly retained in the SF conduit via the second
approach. Furthermore, the suitability of eSF to be processed in
aqueous media, turns it a promising biomaterial for the fabrica-
tion of bioactive protein delivery systems.[21]
Since the importance of NTFs to enhance PNR was noticed, it
has been investigated the importance of their retrograde trans-
port to the cell body.[22] A body of evidence proposes that the
mechanism of NTF retrograde transport is essential for signal
propagation, neuronal development, and prevention of neuronal
degeneration. In the case of PNIs, the retrograde transport of
injury signals is one of the indispensable cellular instruments
leading to regeneration.[23] This mechanism can allow the coor-
dination between the injury site and the cell body, therefore regu-
lating the proper genes to promote neuronal survival. Both NGF
and GDNF have shown to be retrogradely transported,[22b] with
beneficial effects in terms of nerve protection and regeneration,
although with different mechanisms.[24]
The aim of this investigation was to assess the feasibility of
retrograde delivery of GDNF or NGF by eSF conduits, with dis-
tinct release kinetics after different incorporation methods. The
GDNF and NGF biological activities were assessed in vitro with
a primary dorsal root ganglia explants (DRGs) model, after their
direct seeding in Matrigel. The most promising formulation of
NTF-loaded eSF conduit was then implanted in a 10 mm rat sci-
atic nerve injury model and compared to both autograph and eSF
conduit. The 10 mm sciatic nerve injury model was used in order
to create a gap to diminish the effect of distal neurotrophic fac-
tors, and in fact, assess the outcome of the NGCs delivered NTFs.
The data were evaluated based on pinch test, muscle weight, and
proximal nerve histology following sciatic nerve injury.
2. Results
2.1. Production and Physical Characterization of Silk Fibroin
Conduits
SF conduits were successfully produced according to a protocol
previously developed by our group.[3] Briefly, a purified SF solu-
tion was diluted to 16 wt% with distilled water, after which it was
mixed with horseradish peroxidase solution and hydrogen per-
oxide solution for the crosslink. The previous mixture was then
injected within the space between two concentric cylinder molds.
The system was incubated at 37 °C to induce gelation for the
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Figure 1. A) Schematic representation of the methodology used to produce the SF conduits. The methodology allows to fabricate enzymatically
crosslinked SF NGCs following a method previously developed by Carvalho et al., which takes advantage of the tyrosine groups present in the structure
of SF that are known to form a covalently crosslinked hydrogel. B) SEM microphotographs of the conduits incorporating NTFs, by (i) the crosslinking
and (ii) the absorption method, respectively.
Table 1. Samples produced for in vitro assays by means of using the
crosslinking and absorption methods, different NTFs (i.e., GDNF and







GDNF GDNF/C GDNF/A2 GDNF/A4
NGF NGF/C NGF/A2 NGF/A4
period of 30 min. After gelation, a quick immersion in liquid ni-
trogen is needed, followed by an immersion in ethanol to induce
permanent 𝛽-sheet.
Figure 1 depicts a detailed scheme of the production steps, in
which the different methods of NTFs incorporation are repre-
sented. Different formulations were produced, by varying the in-
corporation method (i.e., crosslinking and absorption), the NTF
incorporated (i.e., NGF and GDNF) and the concentration of
NTFs (i.e., 2 µg mL−1 or 4 µg mL−1), as can be seen in Table 1.
The microstructure of the final conduits is shown in Figure S1
(Supporting Information), which shows representative SEM mi-
crographs of the eSF NGCs microstructure.
2.2. Neurotrophic Factors Loading Efficiency
NTFs loading in the eSF conduits was attained by two different
methods designated by crosslinking and absorption.
In the crosslinking method, 4 µg mL−1 of each NTF was incor-
porated in 1 mL of 16% SF solution. The rest of the process was
carried out according to the previous report[3] and was shown in
Figure 1, to finally obtain a freeze-dried eSF NGC. For GDNF and
NGF crosslinked formulations, the loading efficiency can be con-
sidered 100%, as all the amount of growth factor that was added
in the 4 µg mL−1 solution got entrapped in SF structure.
However, the loading efficiency in the absorption method
needed to be determined. For that, ELISA quantification was per-
formed on the remaining NTF solution after the absorption pro-
cess, in order to calculate the amount of growth factor that was, in
fact, absorbed. In Table 2, the loading efficiency determined for
the different formulations is presented. For GDNF/A2 formula-
tion, the loading efficiency reached 78.3 ± 1.25%. A similar value
(77.2 ± 0.85%) was determined for GDNF/A4 formulation. The
retention of NGF by the eSF conduit was inferior when compared
to GDNF, as the loading efficiency of 46.2 ± 0.43% and 44.5 ±
1.02% was observed for NGF/A2 and NGF/A4, respectively.
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Table 2. Loading efficiency verified for the different formulations, shown in
percentage.
Formulation Loading efficiency
GDNF/A2 78.3 ± 1.25%
GDNF/A4 77.2 ± 0.85%
NGF/A2 46.2 ± 0.43%
NGF/A4 44.5 ± 1.02%
2.3. In Vitro Release of NTFs from Silk Conduit
The amount of released GDNF or NGF from the eSF conduits
was quantified daily within the first 5 d and in a cumulative man-
ner up to 50 d, according to the different methods of loading and
concentrations of NTFs (Figure 2). The scheme of the methodol-
ogy used in the NTF release study is depicted in Figure 2A.
The daily GDNF release profile presented in Figure 2B-I re-
veals a significantly higher delivery of the NTF when the loading
is done by means of performing the absorption method as com-
pared to crosslinking method, in all the timepoints. Regarding
the absorption formulations, the highest released was verified in
the first day, with an average of 2.45 ± 0.42 ng mL−1 of released
NTF. It was also verified a reduction of the delivery rate day by
day, from 2.45 ± 0.42 ng mL−1 on day 1 to 1.06 ± 0.12 ng mL−1
on day 5 (GDNF/A4 formulation).
With a slightly overall lower release, there was also a reduc-
tion from 2.19 ± 0.15 ng mL−1 in day 1 to 1.04 ± 0.12 ng
mL−1 in day 5 for GDNF/A4 formulation. The cumulative release
shown in Figure 2B-II reveals that the tendency to slowly decrease
the amount of NTF released is kept throughout the timepoints,
with GDNF/A4 formulation releasing 36.8 ± 0.9 ng mL−1 and
GDNF/A2 releasing 32.3 ± 3.3 ng mL−1 after 50 d. The daily NGF
releasing profile can be seen in Figure 2B-III where, similarly to
GDNF daily release, the higher amount released was verified in
Figure 2. A) Scheme of the methodology used in the NTF release assay. B) ELISA quantification of the NTFs released from the SF conduit, considering
the different methods of incorporation, NTFs used and concentration. B-I) Daily amount of GDNF released from SF conduits within 5 d; B-II) Cumulative
amount of released GDNF within 50 d; B-III) Daily amount of NGF released from SF conduits within 5 d; B-IV) Cumulative amount of released NGF
within 50 d. Results were represented as mean ± SD (n= 3). For multiple comparisons, * symbol indicates the comparison of GDNF/A2or NGF/A2and
crosslinked formulations, # symbol regards comparison of GDNF/A4or NGF/A4and crosslinked formulations. Statistically significant differences were
represented by */#(p< 0.05), **/##(p< 0.01), and ***/###(p< 0.001).
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the first day, but with a more drastic reduction from day 1 to day
2, in a burst release manner. NGF/A4 formulation reduced its re-
lease from 2.23 ± 0.14 ng mL−1 in day 1 to 0.24 ± 0.05 ng mL−1
in day 5, whereas NGF/A2 formulation reduced its release from
1.42 ± 0.12 ng mL−1 on day 1 to 0.11 ± 0.06 ng mL−1 in day 5.
The cumulative release of NGF depicted in Figure 2B-IV shows
that the tendency to decrease NTF release is kept, with NGF/A4
formulation releasing 8.9 ± 2.1 ng mL−1 and NGF/A2 releasing
6.3 ± 2.3 ng mL−1 after 50 d. In all timepoints analyzed and for
both GDNF and NGF, there is a significant statistical difference
between the formulations produced using the absorption method
in comparison to the crosslinked formulations.
When calculations are made in terms of percentage of release
considering the loading efficiency of each formulation, an inverse
tendency is observed regarding the amount of NTF that is incor-
porated. Figure S2 (Supporting Information) reveals a higher per-
centage of release when observing formulations GDNF/A2 and
NGF/A2, as compared to GDNF/A4 and NGF/A4. A high amount
of NTF remains in the conduits when 4 µg mL−1 are incorpo-
rated.
2.4. NTFs Bioactivity Assay with DRGs
The responses of the DRGs when subjected to the different con-
ditions and different NTFs were evaluated in terms of neurite out-
growth (Figure 3), after seeding in Matrigel. The scheme of the
methodology used in the bioactivity assay in vitro is presented in
Figure 3A. DRGs responses to GDNF can be observed qualita-
tively and quantitatively in Figure 3B,C, respectively. GDNF/A4
formulation presented the highest values for all the parame-
ters, whereas the crosslinked formulation presented the lowest,
even lower than the negative control. More specifically, in terms
of neurite length, there is a significant difference between the
crosslinked samples (GDNF/C) and both absorption formula-
tions (GDNF/A2 and GDNF/A4), where the longest neurites ex-
tended for an average of 122.8± 119.3, 595.2± 246.2, and 759.0±
160.7 µm, respectively. For the positive control and negative con-
trol, neurite length achieved values of 961.7 ± 197.8 and 492.0 ±
170.5 µm, respectively. Regarding cellular migration from the
DRG body, there was no significant differences between the val-
ues obtained for all the tested groups. The values obtained for
the tested formulations (GDNF/C, GDNF/A2 and GDNF/A4), are
712.8 ± 281.3 µm, 1422.1 ± 417.6 µm, and 1525.8 ± 384.9 µm, re-
spectively. For the positive and negative control, the values were
1307.3 ± 266.9 µm and 854.7 ± 282.9 µm. In what concerns
the percentage of field coverage, the values obtained were 1.3 ±
0.8%, 4.4 ± 1.5%, and 10.9 ± 1.6% for GDNF/C, GDNF/A2 and
GDNF/A4 formulations, respectively. In the positive and negative
controls, values of 15.6 ± 5.3% and 3.1 ± 1.3% were obtained,
respectively. For this parameter, a statistically significant differ-
ence was observed for GDNF/A4 formulation when compared
to GDNF/C and GDNF/A2 samples. A summary of the above-
mentioned information regarding GDNF treated DRGs can be
found in Table S1 (Supporting Information).
DRGs responses to NGF can be seen qualitatively and quan-
titatively in Figure 3D,E, respectively. The results obtained with
NGF followed the same pattern as with GDNF. The NGF/A4
formulation presented consistently higher values as compared
to NGF/A2 formulation, whereas lower neurite outgrowth was
observed for NGF/C when compared to the negative control.
More precisely, the neurite length reached values of 1072.6 ±
227.4 µm for the positive control and 492.0 ± 170.5 µm for the
negative control. Regarding the formulations NGF/C, NGF/A2
and NGF/A4, the determined values were 220.5 ± 116.6, 641.1 ±
176.4, and 870.9 ± 246.7 µm, respectively. For this parameter,
significant statistical differences were found between all the for-
mulations containing NGF. For cellular migration, image anal-
ysis indicated a migration of 1464.8 ± 262.9 µm for the positive
control and 854.7 ± 282.9 µm for the negative control. Regard-
ing the formulations NGF/A2 and NGF/A4, the measured val-
ues were 1196.2 ± 285.6 and 1560.4 ± 403.6 µm, respectively.
In contrast, for NGF/C, no cellular migration was observed. A
significant statistical difference was found between NGF/A2 and
NGF/A4. For the percentage of field coverage obtained with NGF
formulations, the values for the formulations NGF/C, NGF/A2
and NGF/A4 were 8 ± 1.6%, 4.2 ± 1.0%, and 7 ± 1.4%, respec-
tively. On the other hand, values of 7.0 ± 1.3% and 3.1 ± 1.3%
were determined for the positive control and negative control, re-
spectively. Significant statistical differences were found between
the two NGF absorption formulations and between NGF/A4 and
NGF/C formulation. A summary of above-mentioned informa-
tion regarding NGF treated DRGs can be found in Table S2 (Sup-
porting Information).
When comparing GDNF/A4 with NGF/A4 in terms of percent-
age of field coverage (Figure 4), which reflects both the length and
density of neurite outgrowth, it was observed a statistically signif-
icant difference between them, with values of 10.9 ± 1.6% and
7 ± 1.4%, respectively. Due to the statistically significant differ-
ent results obtained between both NTFs, GDNF/A4 formulation
was selected to proceed with further in vivo studies.
Taking a closer look at the confocal images, it is clear that
the migratory stage of Schwann cells and the secretion of
laminin cues closely interacts with axons (Figure S3, Support-
ing Information).[25] It was also interesting to observe the axon
physiology in the DRGs, where nucleated cells, assumed to be
Schwann cells, were surrounding the growing neurites to form
the myelin sheets.[26] Another axon’s typical structure, the termi-
nal button, is visible in Figure S4 (Supporting Information), con-
firming the presence of growing axons.
2.5. In Vivo Study
Three different study groups were tested in vivo. The autograft,
eSF and GDNF/A4 were implanted in a 10 mm sciatic nerve de-
fect in rats, by performing a sciatic nerve resection.
The 3D printed tool allowed for a very clean and precise cut of
the sciatic nerve, in the exact required position. All experimental
animals tolerated the anesthesia and surgery and survived until
the end of the observation period. Throughout the 6 weeks of in
vivo experiment, animals were checked at least once a day and
no complications were observed. All rats recovered well, without
any sign of infection in the wounds, which healed completely ap-
proximately one week after surgery.
No signs of ulcers or autophagy were verified in the paws of any
of the 15 operated rats. Overall, no visible distress was detected
in the animals after surgery. At the time of explantation, no signs
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Figure 4. Impact of the different GDNF or NGF formulations on DRGs
percentage of field coverage (which reflects both the length and density of
neurite outgrowth). When considering the 4 µg mL−1concentration, there
is a significant statistical difference between GDNF/A4and NGF/A4treated
DRGs in terms of percentage of field coverage. Results were represented
as mean ± SD (n= 3) with at least five DRGs per condition being analyzed
in each experiment. Statistically significant differences were represented
by * (p< 0.05), ** (p< 0.01), and *** (p< 0.001). Scale bar: 500 µm.
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of necrosis, acute inflammatory reaction, and calcifications were
observed in the implant site and apparently, healthy connective
tissue was observed surrounding all the explants.
The results of the pinch test can be seen in the Table 3. At 6
weeks post-surgery, the distal segment of the nerve was isolated
and stimulated with a pinch by forceps. Contraction of muscle on
the back or retraction of the leg indicates the presence of regen-
erating fibers in the pinched segment.
After sacrificing the animals, a few standard evaluations were
performed, that are capable of indicating the level of success in
the nerve regenerative process, by comparing the SF with and
without GDNF, against the autograft. Measurements of percent-
age of muscle weight loss, and quantitative as well as qualitative
measurements of longitudinal nerve area in histological images
are shown in Figure 5.
In Figure 5A, the different in vivo study groups: autograft, eSF,
and GDNF/A4, implanted in the animals are shown. Nerve regen-
eration was further assessed through the percentage of muscle
weight loss, which was determined to be 73.3± 2.7%, 79.8± 1.3%
and 76.6 ± 2.6% for the autograft, eSF and GDNF/A4 groups, re-
spectively, as can be seen in Figure 5B. The results illustrate that
plain eSF NGC lead to a significant increase in terms of percent-
age of muscle weight loss (p < 0.01), when compared to the au-
tograft. However, when using GDNF formulation, no significant
differences were found. These results suggest that the integra-
tion of GDNF decreases the percentage of muscle weight loss,
leading to improved functional recovery.
After analyzing the H&E stained longitudinal sections, a re-
generation cable across the 10 mm nerve gap was observed in
100% of the autografts (5/5), 80% in the eSF conduits (4/5) and
100% of the GDNF/A4 (5/5). Furthermore, it was found that the
longitudinal sectional nerve area was significantly higher in the
GDNF/A4 when compared to eSF (Figure 5C), where the values
obtained were 832.68 ± 293.15, 390.55 ± 130.18, and, 950.99 ±
239.58 µm2 for the autograft, eSF conduit and GDNF/A4, respec-
tively. This result can be seen qualitatively in Figures 5D. The
difference in the thickness of the nerve cable can evidently be
seen in a cross-section of the NGCs, where the thickness of the
cable roughly doubles from eSF to GDNF/A4, as can be seen in
Figure 5E.
Histological procedures can be seen in Figure 6. Explanted
samples were cut for histological procedures according to the
scheme in Figure 6A.
Semithin cross-sections were observed under a light micro-
scope for a proximal area analysis (PNX section, view at the
point of 3 mm outside the conduit), after osmium tetroxide stain-
ing. The number of regenerated myelinated nerve fibers detected
(Figure 6B) was similar in the case of the autograft (5443 ±
985) and the GDNF/A4 formulation (4916 ± 305), but signifi-
cantly higher in the eSF formulation (9281 ± 2957). The healthy
contralateral side contains an average of 6110 ± 745 myeli-
nated axons. Qualitatively, the nerve histological image from the
GDNF/A4 formulations resembles the one from the autograft,
while the eSF formulation presented a distinct microstructure
(Figure 6C). Proximal myelinated axons are larger and have a
more uniform appearance in the autograft and GDNF/A4 for-
mulations. This contrasts with the very irregular shaped and
sized axons in the eSF formulations. In the same cross-sectional
Figure 3. A) Scheme of the methodology used in the bioactivity assay in vitro. Arrows point to the location of DRGs harvest, close to the spinal cord.
B) Representative confocal fluorescent images of DRGs stained with Neurofilament 200 (in green) after being treated with GDNF released from SF
conduits. C) Quantification of different parameters related to the DRGs neurite outgrowth, such as neurite length, cellular migration from DRG body
and percentage of field coverage after being in contact with GDNF releasing SF conduits. D) Representative confocal fluorescent images of DRGs stained
with Neurofilament 200 (in green) after being treated with NGF released from SF conduits. E) Quantification of different parameters related to the DRGs
neurite outgrowth, such as neurite length, cellular migration from DRG body and percentage of field coverage after being in contact with NGF releasing
SF conduits. Results were represented as mean ± SD (n= 3) with at least five DRGs per condition being analyzed in each experiment. Statistically
significant differences were represented by * (p< 0.05), ** (p< 0.01), and *** (p< 0.001). Scale bar: B,D) 500 µm.
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Figure 5. A) Implantation of the different in vivo study groups: autograft, SF and GDNF/A4 (n= 5). B) Immediately after animal sacrifice, the percentage
of muscle weight loss was determined. C) Quantitative measurements of the longitudinal sectional nerve area. Measurements were made in the middle
of the conduit (since the proximal area was cut for histomorphometric analyses, the measurement was performed 7 mm from the distal stump).
D) Representative photomicrographs of the longitudinal sections of implanted autograft, SF and GDNF/A4 after hematoxylin-eosin (HE) staining.
E) Representative photograph showing the difference in the regenerated nerve cable thickness. Results were represented as mean ± SD. Statistically
significant differences were represented by * (p< 0.05), ** (p< 0.01), and *** (p< 0.001). Scale bars: A) 500 µm; D) 500 µm; E) 250 µm (left) and 500 µm
(right).
area (PNX), blood vessel-like quantification was performed, both
qualitatively (Figure S5, Supporting Information) and quantita-
tively (Figure S6, Supporting Information). The results showed
a significant difference between the autograft and the eSF con-
duits with and without GDNF. A significant increase in the
blood vessel-like structure number was verified in the presence
of GDNF/A4 conduits, when compared to nerves reconstructed
with plain eSF conduit.
3. Discussion
The lack of a pivotal breakthrough in PNR field is leading sci-
entists and medical community to search for new and innova-
tive ways to tackle the problem. Consequently, TE is receiving
increasing attention in the treatment of PNI.[27] As the classi-
cal FDA-approved NGCs do not provide sufficiently good results
in terms of functional recovery, alternative strategies consider-
ing the mimicry of natural microenvironment and incorporation
of physical and chemical cues for optimal axon guiding became
crucial.[28] Furthermore, several works confirmed that NGCs re-
leasing NTFs can improve nerve regeneration across long nerve
gaps.[29]
Including NTFs in a matrix is a required step since simple
administration of NTFs is not sufficient to achieve an effective
concentration over a suitable time period that would ultimately
promote nerve repair. This is due to their rapid diffusion in the
body fluids and destruction by proteolytic enzymes.[30] In this
context, the present study demonstrated the beneficial effects of
controlled delivery of two PNS prominent growth factors, i.e.,
GDNF and NGF, in a way to reproduce the native NTF distri-
bution during the nervous system development, therefore stim-
ulating PNR.[18] Moreover, different ways of immobilizing NTFs
using a previously described production method of eSF conduits
were investigated.[3]
SF was selected for developing NGCs because of its well-
known biocompatibility, good mechanical properties and friendly
processing.[31] The stability and bioactivity of NTFs during pro-
cessing is enhanced when using mild processing conditions,
which is the case of the eSF, where no organic solvents or harsh
reagents were used.
For the crosslinking method, the loading efficiency can be con-
sidered as 100%. In contrast, for the absorption method, it has
been hypothesized that two different mechanisms contribute to
maintaining the NTFs within the eSF conduit. The first relates to
the liquid absorption by the porous eSF wall, associated with the
swelling capability of the material. The second regards the elec-
trostatic interactions that occur between the negatively charged
eSF and the positively charged NTFs,[32] which play a crucial role
in this process. In this sense, the affinity of GDNF or NGF pro-
teins to the eSF conduit can partially determine its loading effi-
ciency and give rise to a differential absorption/adsorption. The
finest way to calculate the loading efficiency should be using the
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Figure 6. A) Schematic representation of the cross- and longitudinal sections positioning for histological analysis. B) Quantitative evaluation of myeli-
nated axons in the proximal area (PNX) (n= 5), where results were represented as mean ± SD and statistically significant differences were represented
by * (p< 0.05), ** (p< 0.01), and *** (p< 0.001). C) Light microscopy representative images of semithin nerve cross-sections in the PNX cross-sectional
area, after osmium tetroxide and toluidine blue staining. On the right, close-up images of each in vivo study groups. Scale bars: 20 µm.
known concentration to subtract the remaining NTF in the tube.
Either way, the ELISA may not be able to interact with degraded
NTF. The actual loading efficiency may not be truly reflected by
ELISA method. However, the method may be ideal for our study
because there is only electrostatic connections or weaker bonds
between the NTF and the silk fibroin structure.
It is an evidence that GDNF tends to bind more strongly to the
eSF conduit, as seen by the 30% discrepancy between absorp-
tion efficiencies in GDNF and NGF. Without any other variables
in the process, this differential absorption could be explained by
the molecular/ionic affinity to eSF, which is higher in the case of
GDNF, having a higher positive charge when compared to NGF.
This is due to the fact that GDNF has an amino-acid rich se-
quence of 16 N-terminal residues.[33] In this context, it can be
predicted that higher NTFs loading implies higher release. The
higher affinity binding of GDNF to the SF conduit was visible in
its daily release profile, where GDNF has a more sustained re-
lease when compared to the burst release observed in the NGF
loaded conduits. Similarly, the same principle of higher load-
ing resulting in higher release was verified for both GDNF and
NGF, as the GDNF/A4 and NGF/A4 formulations released higher
amounts of NTFs than GDNF/A2 and NGF/A2. When compar-
ing the crosslinking to the absorption method, and given the fact
that the same amounts of NTF were loaded in the crosslinked
4 µg mL−1 and absorption 4 µg mL−1 formulations, the minute
amounts of NTFs released in the crosslinked formulation evi-
dences the initial hypothesis of stronger molecular entrapment
and difficulty to diffuse across the conduit wall. Furthermore, in
addition to the expected entrapment of NTFs in the SF matrix, we
hypothesize that NTFs could have been covalently linked to each
other and to SF tyrosine groups.
It is a fact that SF is a slow-degrading biomaterial. This has
been proven in several other publications and the exact degrada-
tion profile of the developed enzymatic crosslinked SF conduits
has been assessed in another publication.[3] Such degradation
profile is obtained by mimicking physiologic conditions (by im-
mersion in Protease XIV at 37 °C). Therefore, it is assumed that
the degradation profile happening in vivo is similar to what was
previously defined. Degradation is a normal process transversal
to all biomaterials, and authors expect a constant release of the
growth factors as the conduits are being slowly degraded. In fact,
the steady and slow degradation of SF when implanted is con-
tributing to the release and consequent action of GDNF in situ.
Overall, the quantity of GDNF and NGF released by GDNF/A4
and NGF/A4 formulations, respectively, were similar and in
the range of the release values reported in the literature, also
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demonstrating that the absorption/surface binding which occurs
during the absorption process allowed the NTFs to maintain a rel-
atively stable and adequate concentration.[18,20] Controlled release
of GDNF and NGF in the range of 1–10 ng mL−1 from SF-based
NGCs has been suggested to be optimal for nerve repair,[34] which
was also verified in our experimental work.
We then investigated the effect of the different formulations
on neurite outgrowth of freshly isolated DRGs in vitro, seeded
on Matrigel. Matrigel was selected as substrate, since DRGs are
highly mechanosensitive and its hydrogel-like stiffness repre-
sents the optimal surface for regeneration.[25,35] Furthermore, in
the case of negative control, despite the absence of added NTFs,
neurite outgrowth was observed since Matrigel can be consid-
ered a permissive substrate,[36] very rich in extracellular matrix
(ECM) proteins, namely laminin, which is optimal for neuronal
cells attachment.[37] Matrigel has been routinely used in preclin-
ical studies for neuronal cells’ adhesion and proliferation and its
effect in neurite extension has been studied.[37c] DRG neurons
are constituents of the peripheral sensory nervous system and
one of the best models to study PNR.[38] The parameters eval-
uated were the conventional neurite length, cellular migration
from DRG body and percentage of field coverage. The pattern
of the results was similar for GDNF- and NGF-treated ganglia,
where neurite outgrowth reached its maximum in the GDNF/A4
and NGF/A4 formulations, followed by the intermediate values
obtained by GDNF/A2 and NGF/A2. The crosslinked formula-
tions, i.e., GDNF/C and NGF/C, presented the lowest values for
neurite outgrowth. Such results are in accordance with their re-
spective releasing profile, where higher amounts of released NTF
led to increased neurite length, cellular migration, and percent-
age of field coverage. The results are also in accordance with other
reports, where DRGs were shown to respond to concentrations
of 1–2 ng mL−1 of GDNF or NGF.[20] Although we initially pre-
dicted good outcomes from the crosslinking formulations by pre-
venting NTF burst release, the in vitro results showed otherwise.
We can hypothesize that, when compared to the negative con-
trol, the poor performance of the crosslinked formulations can
be explained by the fact that both NTFs are rich in tyrosine amino
acid, possibly leading to an enzymatic crosslinking between SF
and NTFs. This covalent binding can result in the slow release
of the NTFs, which can be beneficial for long-term applications
of the eSF conduits such as the case of the regeneration of long-
gaps.[39] However, the low amounts released still seem to have an
undesired effect on neurite outgrowth, possibly due to binding
of the GF to the receptors, occupying or blocking them. In this
scenario, the ECM molecules that have a favorable effect in the
presence of Matrigel (also present in the negative control) would
not be able to act in the crosslinked formulation.
A strong correlation was found between cellular migration and
neurite outgrowth.[40] It was evident in the confocal images that
cellular components that were isolated with the DRGs, namely
Schwann cells and fibroblasts, were paving the way for neu-
rite growth. Only in the case of visible cellular proliferation and
spreading, neurite outgrowth would be detected.
Neurite length in the positive control is similar to what is
found in the literature, with an average growth of 100–200 µm
per day, validating our study.[41] It has been shown that Schwann
cell proliferation and migration play a crucial role during nerve
regeneration.[42] Therefore, it is possible to predict that which
NTF is able to promote a higher Schwann cell migration, is also
capable of further enhancing the in vivo outcomes. Through con-
focal images, it was possible to observe that the path of neurites
outgrowth was guided by cellular components (fibroblasts and
Schwann cells). Therefore, the two parameters are connected as
demonstrated by the fact that the greater cellular migration led
to more extensive the neurite growth. It was interesting to be
able to correlate those two facts, that were true for all formula-
tions (please see Figure S3 in the Supporting Information). In
conclusion, to have neurite elongation, cellular migration is also
necessary and both parameters are intrinsically correlated. It was
observed that less amounts of released NGF (up to 5 d) are more
efficient and have a more intense effects on neurite elongation as
compared to GDNF (since less ng released provide similar neu-
rite extension). But when comparing NGF/A2 and NGF/A4, the
higher amount of NGF released by NGF/A4 is crucial and makes
the significant difference. If this were the only focus of the study,
NGF would be the first choice. However, neurite density is an im-
portant parameter as well, and at this point the clear front-runner
is GDNF. Concerning DRG in vitro study, DRGs are considered
sensory neurons and they appear responds to NGF in a differ-
ent manner. Also, from the study we can tell NGF is more dose
depend than GDNF.
Together with the ELISA results, the in vitro biological tests
allowed to exclude any crosslinked formulation for further stud-
ies and elect the GDNF/A4 and NGF/A4 as the most promising
formulations. In our study, GDNF and NGF prompted similar
neurite elongation, but GDNF increased the neurite density. In
this context, GDNF/A4 was selected for the in vivo evaluation
since its percentage of field coverage was significantly higher
than NGF/A4.
Considering the results from the in vivo study, the presence
of GDNF significantly promoted motor reinnervation and motor
fibers survival, as the muscle weight loss or atrophy was signifi-
cantly avoided in the gastrocnemius muscle, when compared to
the SF samples, which was critical for functional recovery.[43] On
the other hand, in relation to the pinch test, the reflex shown by
most of the animals in the GDNF/A4 study group, proves that
GDNF could act on sensory reinnervation.[44] According to our
literature research, the pinch test is “a test where reflex move-
ment of the back muscles or retraction of the leg indicate the
presence of sensory fibers in the pinched segment while no re-
sponse indicates as the absence of such fibers.”[44] Such test can
be done by pinching the nerve segment distal to the conduit, as
was performed in our experimental work. These findings could
be related to the in vitro biological observations, where sensory
DRGs positively respond to GDNF.
Longitudinal H&E sections allowed to study the general nerve
regeneration potential of the different formulations. A complete
fibrin nerve cable formation is essential for obtaining a complete
nerve regeneration with functional recovery. Longitudinal sec-
tional nerve area and number of samples in which the nerve cable
was able to cross the 10 mm gap, point to GDNF supplemented
SF conduits to significantly outperform the SF formulation.
It has to be taken in consideration that the active retrograde
transport of growth factors is crucial for the normal function of
nerves, and disorders in this mechanism result in neurodegen-
eration, neuropathies and cell death.[45] Signaling proteins fre-
quently travel from the axon terminals to the cell body in order to
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trigger and stimulate their signaling pathways. In the case of an
injury, NTFs released by the native tissue are transported to the
cell bodies, in order to promote survival mechanisms.[46] In this
experimental work, a simple osmium tetroxide/toluidine blue
staining allowed to assess that GDNF/A4 formulation showed
better retrograde nerve protection and nerve trunk protection
when compared to the SF conduit.[47] In the proximal area, with-
out the GDNF being transported backwards, SF reconstructed
nerves suffered from significant degeneration. It is noteworthy
that many axons began sprouting from proximal site. However,
this indicated that nerve was severely damaged.[48] In this sce-
nario, the regeneration may be delayed or failed.
Only recently the scientific community has realized the im-
portance of vascularization in PNR. In fact, the lack of blood
supply is one of the most important and limiting factors im-
pairing regeneration.[49] Although no specific vascularization
staining was performed, blood vessels-like structures are well
identified in the toluidine blue staining because of the visible
endothelial wall, shape and presence of erythrocytes.[50] The sig-
nificant increment on blood vessel-like structure number in the
nerve regenerated within the GDNF/A4 conduit demonstrated
the beneficial environment provided by the developed NGC,
while confirming the direct relationship between nerve regener-
ation and angiogenesis.[51] It has been shown that not only the
new vasculature reduces hypoxia in the regenerating nerve, but
Schwann cells use the blood vessels present in the proximal nerve
as “tracks” to cross and migrate through the bridge, taking re-
growing axons with them.[52] These results confirm other reports,
where certain GDNF peptides are described as potent angiogenic
factors.[53] Thus, all evidence withdrew from this study points to
the gainful effects of trophically functionalizing NGCs.
The advantageous effects of an NGC on nerve repair will diffi-
cultly achieve a similar performance than an autograft. Still, the
developed GDNF loaded SF conduit performed similarly to the
autograft in the variety of parameters evaluated, namely in what
concerns the quality of the regenerated nerve cable and recovery
of nerve function (assessed by the pinch test). Although a 6-week
period for nerve regeneration can be considered short and early
for some assessments, such as electrophysiological evaluations,
the fact that significant statistical differences were found between
the studied formulations in some parameters, confirms that ef-
fective conclusions can be made from this study.
4. Conclusion
In this study, we have demonstrated that the enzymatically
crosslinked silk fibroin conduits may be loaded with two differ-
ent neurotrophic factors, via different methodologies. They pre-
sented distinctive releasing profiles, according to their affinity to
silk fibroin. In vitro, the superior releasing profile of GDNF could
be assessed when it was incorporated by the adsorption method
at the concentration of 4 µg mL−1. These results were confirmed
when DRGs’ neurite density was significantly enhanced in the
presence of such formulation. Furthermore, the valuable effects
of GDNF/A4 on improving nerve regeneration in vivo resulted
in a suitable environment for peripheral nerve regeneration. Im-
planting such formulation on a 10 mm rat sciatic nerve defect
acted on both sensory and motor fibers, as was perceived by the
specific assays of pinch test and percentage of muscle weight
loss. Related to the histological and histomorphometrical eval-
uation, when using the absorbed GDNF formulation, proximal
nerve protection was found to be more robust when compared
to plain silk fibroin conduit and comparable to the autograft, via
retrograde transport of GDNF. Vascularization was also signifi-
cantly increased by the addition of GDNF to silk fibroin, which
represents another gain in terms of nerve regeneration.
Overall, the addition of GDNF to the silk fibroin conduit could
be one possible treatment to prevent neurodegeneration. The
findings from this experimental work could significantly con-
tribute to TE field. It is our firm belief that the developed GDNF-
incorporating silk fibroin conduit is a promising candidate for fu-
ture studies, where cellular therapies and guiding luminal fillers
might be included, creating new and multifactorial therapeutic
alternatives for the treatment of peripheral nerve injuries.
5. Experimental Section
Materials: Bombyx mori cocoons were supplied by the Portuguese
Association of Parents and Friends of Mentally Disabled Citizens (AP-
PACDM, Portugal). Hydrogen peroxide was purchased from Panreac
(Spain). Human recombinant GDNF (cat#450-10-10 µg) and Human re-
combinant NGF (cat#450-01-100 µg) were purchased from Peprotech
(USA). Human GDNF Duoset ELISA kit (cat#DY212) and Human 𝛽-NGF
Duoset ELISA kit (cat#DY256) were purchased from R&D Systems (USA).
Corning Matrigel phenol red-free was purchased from VWR (USA). Other
materials and reagents were purchased from Sigma–Aldrich (USA).
Preparation of Silk Fibroin (SF) Conduits: The purification of SF
and consequent preparation of eSF NGCs was prepared as described
elsewhere.[3] Briefly, SF was detached from the other main protein present
in the cocoons, sericin. For this purpose, the cocoons were immersed in a
0.02 m boiling sodium carbonate solution for 1 h, followed by rinsing with
abundant distilled water. The obtained SF was then dissolved in a 9.3 m
lithium bromide solution at 70 °C for 1 h and dialyzed (benzoylated dialysis
tubing, MWCO: 2 kDa) against distilled water for 48 h to remove contami-
nations. The purified SF was concentrated against a 20 wt% poly(ethylene
glycol) solution for at least 6 h, and the final concentration was determined
by weighting the dry product after drying at 70 °C overnight. After deter-
mining the concentration, the SF solution was diluted to 16 wt% with dis-
tilled water, and mixed with horseradish peroxidase solution (HRP type VI,
0.84 mg mL−1, 100 µL) and hydrogen peroxide solution (H2O2, 0.36 wt%,
65 µL) for enzymatic crosslinking following the procedure described by
Yan et al.[54] In order to produce the conduits, the previous mixture was
injected within the space between two concentric cylinder molds, where
the outer cylinder had a diameter of 4 mm and the inner cylinder had a
diameter of 2 mm. The system was incubated at 37 °C for the period of 1 h
in order to induce gelation. After gelation, a quick immersion in liquid ni-
trogen is needed to remove the outer mold, followed by an immersion in
ethanol 100 vol% to induce permanent crystalline 𝛽-sheet conformation
and to remove the inner mold. The obtained hollow conduits were sub-
jected to a process of lyophilization for 72 h.[3] Final conduits had a wall
thickness of ≈700 µm, a lumen diameter of ≈5 mm and an external pore
size in the range of 3–6 µm. Conduits were cut to a total length of 14 mm
for all assays.
Physical Characterization of the Conduits: The morphology of the pro-
duced eSF conduits was assessed under a scanning electron microscope
(model S360, Leica, Cambridge, UK). The specimens were sputter coated
with gold, prior to the analysis of surface morphology and microstructure.
Incorporation of NTFs: The incorporation of NTFs was achieved via two
different methods, which will be designated throughout the manuscript:
i) crosslinking method, and ii) absorption method. For the crosslinking
method, a NTF solution of 4 µg mL−1 in PBS was added to 1 mL of aque-
ous SF solution. As described in the preparation of the conduits, the solu-
tion was mixed with HRP and H2O2, allowing the NTFs to be entrapped in
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the conduits’ walls after crosslinking. The processing was then carried out
as previously described. For the adsorption method, the conduits’ prepa-
ration was conducted following the indicated protocol. Final lyophilized
conduits (made of 1 mL of SF solution) were immersed in 1 mL of a 4 µg
mL−1 or 2 µg mL−1 of NTF solution in PBS for 3 h at 37 °C. A second step of
lyophilization was performed. The NTFs incorporated in the eSF conduits
by crosslinking and absorption were GDNF and NGF. A table identifying
the six produced samples is shown in Table 1.
Determination of NTFs’ Loading Efficiency in eSF Conduits: After the
production of the different samples indicated in Table 1, the NTFs’ loading
efficiency in the eSF conduits was determined using the enzyme-linked im-
munosorbent assay (ELISA) kits for GDNF and NGF, respectively. These
experiments were only carried for the absorption method, since it can be
predicted that 100% of NTF was incorporated in the crosslinking method.
Considering that the initial NTF solutions had the concentration of 2 and
4 µg mL−1, the NTF solutions that remained after the absorption process
were frozen at -20 °C, stored and later subjected to ELISA quantification. In
order to determine the percentage of NTFs’ loading efficiency, Equation (1)
was applied, where Ci represents the initial NTF concentration in which
the conduit was soaked, and x represents NTF quantification obtained by
ELISA. A triplicate of samples was measured in three independent experi-
ments, and the results were expressed as mean ± SD.
% NTF of loading efficiency = 100 − x × 100
Ci
(1)
In Vitro Release of NTFs from the Nerve Conduits: The amount of NTFs
released from the eSF conduits was quantified by ELISA according to the
manufacturer’s instructions. Each eSF conduit, with the size of 14 mm in
length, was incubated in 1 mL of release medium (1 wt% BSA in PBS) at
37 °C, with shaking at 60 rpm, for 50 d. The supernatant was collected and
substituted with 1 mL of fresh release medium every 24 h. The absorbance
was measured in the collected solutions at 450 nm using a plate reader
(Tecan, Spark 10M, Switzerland). The NTFs concentration was determined
by means of comparing the reading to the obtained standard curve after
normalization
In Vitro Isolation and Culturing of DRGs for NTFs Bioactivity Assay: The
biological activity of the NTFs released from the eSF conduits was as-
sessed by determining the axonal outgrowth of DRGs. DRGs explants were
isolated from neonatal rat pups (considered neonatal from day 1 to day 5).
They were aseptically harvested and cleaned with dissecting forceps to re-
move the tails and excessive connective tissue. After cutting the DRGs in
halves, they were immediately seeded on Matrigel coated wells. The Ma-
trigel coating was done at least 3 h before the DRGs seeding, using cold
Matrigel (4 °C) and allowing it to polymerize at 37 °C. The DRGs were kept
in regular Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10 vol% fetal bovine serum and 1 vol% penicillin/streptomycin for
the first 24 h, allowing cellular attachment. DRGs were plated at a den-
sity of two DRGs per well. At the same time, the NTF loaded eSF con-
duits were immersed in 1 mL of complete DMEM and incubated at 37
°C and 60 rpm, producing a NTF enriched media, denominated as con-
ditioned media. Every 24 h, the conditioned media was transferred to the
wells containing DRGs and replaced with fresh media. For this assay, the
negative control consisted of DRGs treated with regular DMEM and the
positive control comprised DMEM media supplemented with 50 ng mL−1
of GDNF or NGF. DRGs were cultured with this methodology for 5 d, at 37
°C and 5% CO2. This assay was performed three independent times, with
six DRGs per condition each time.
Immunocytochemistry: After 5 d of incubation, DRGs and cells were
fixed with 4 vol% paraformaldehyde for 30 min. DRGs were washed and
treated with Triton 0.2 vol% in PBS for 10 min for permeabilization pur-
poses. The next step consisted in adding blocking buffer comprising 3 wt%
BSA in PBS, at room temperature (RT), for 30 min. The primary antibody,
diluted in 1 wt% BSA in PBS, was then added, and the mixture incubated
for 1 h at RT (1:150, Monoclonal Anti-Neurofilament 200, produced in
mouse). After washing with PBS, the secondary antibody was immediately
added and incubated for 1 h at RT, protected from light (1:500, Alexa Fluor
488 goat anti-mouse). The last step consisted in nuclei staining, in which
Hoechst staining was applied for 5 min (1:5000).
Image Acquisition and Data Analysis: The stained DRGs were analyzed
using the confocal laser microscope (Leica). Confocal images were ac-
quired and mounted together to fit in a black square (with the exact same
size in all images) so that it would be possible to do image analysis and
comparable quantifications. Fluorescent images were imported to ImageJ
software (Fiji) and three parameters were analyzed and quantified con-
cerning the DRGs neurite outgrowth: neurite length, cellular migration,
and percentage of field coverage.[55] For neurite length and cellular mi-
gration quantifications, the average of the 20 longest neurites and the 20
furthest cells in each image were measured, in a total of five images per
condition.[56] For percentage of field coverage, ImageJ was also used to
convert the pictures to black and white (threshold of 58 for all images)
and the % of white pixels in the black field was quantified. After statistical
analysis, the group presenting the best performance was selected for the
animal study and compared with autograft.
Animal Study: Three different study groups were investigated in vivo
on a 10 mm sciatic nerve defect in rats, including: autograft (n = 5),
eSF (n = 5) and GDNF/A4 (n = 5). The autograft group was the posi-
tive control and the eSF group was the negative control to assess the effi-
cacy of GDNF/A4. The degree of nerve regeneration was assessed after 6
weeks post-implantation. All animals were carefully maintained according
to methods approved by the Institutional Animal Care and Use Committee
at the Rutgers University and the National Institutes of Health regulations
and standards for animal usage were followed.
Surgical Procedure: Male Lewis rats weighing 250–300 g (Charles River
Labs, USA) were anesthetized with isoflurane inhalation (1–5% isoflurane
in 100% O2) via an appropriate face mask, which was kept throughout
the surgical procedure for anesthesia maintenance. Animals were kept on
a heated pad until they recovered from anesthesia. Before the surgery,
Buprenorphine (for analgesic purposes, 0.05 mg kg−1) and Baytril (for
antibiotic purposes, 5 mg kg−1) were administered subcutaneously. After
shaving the surgical site on the left limb, local anesthesia (Bupivacaine,
diluted to 0.25%, 2.5 mg kg−1) was also administered in the place of in-
cision. The shaved area was then cleaned by alternating applications of
chlorhexidine and 70 vol% isopropyl alcohol in circular motions.
Nerve cutting tools were printed from poly(lactic acid) on a Mono-
price fused deposition modeling printer. Tools were designed with a hook
presenting an inner diameter of 2.5 mm and a scalpel alignment groove
700 µm in width. Tools had a beveled tip and specific dimensions to al-
low for minimal tissue damage while exposing and sectioning the nerve.
Printed tools were cleaned in ethanol, individually packed and surgically
sterilized with ethylene oxide. A scheme of a nerve cutting tool can be
seen in Figure S6 (Supporting Information).
For the conduits’ groups, a 5 mm section of the sciatic nerve was re-
moved with the aid of the above-described nerve cutting tool, and the nerve
stumps were allowed to retract to form a 10 mm gap. Sterile conduits
(14 mm in length) were first hydrated for 10 min with sterile saline and then
sutured to the nerve stumps using two 9-0 epineurial sutures on each end,
maintaining the 10 mm gap between the stumps. In that process, nerve
stumps were secured approximately 1 mm into each end of the conduit. In
the case of autografts, a 10 mm segment of nerve was removed, reversed,
and sutured back in the gap using 9-0 sutures on each end. Both muscular
and skin tissues were sutured in layers using absorbable 5-0 sutures. For
postoperative analgesia, buprenorphine SR (1 mg Kg−1) was administered
8 h after the surgery. Animals were checked at least once a day.
Six weeks after surgery, rats were deeply anesthetized using the same
method. The analyzed groups were harvested (SF conduits containing the
regenerated nerves and the autografts were collected, on the experimental
side), as well as a segment of uninjured nerve on the contralateral side, for
comparison purposes. Still under general anesthesia, animals were euth-
anized by carbon dioxide asphyxiation.
Pinch Test: A pinch test was performed in a way to assess sen-
sory functional recovery. The distal nerve segment was pinched with a
pair of forceps to determine any reflex of the ipsilateral side. Every an-
imal of every group was subjected to this test, repeated at least three
times.[44,57]
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Gastrocnemius Muscle Harvest and Weight Ratio: Upon nerve harvest
and after animal sacrifice, the gastrocnemius muscle of both hind limbs
(operated side and contralateral healthy side) were immediately harvested
by exposing the musculature via a knee to ankle longitudinal skin incision.
The muscles were harvested from origin to insertion and weighed with
an electronic balance in order to be able to determine the muscle atrophy
resultant from muscle denervation. Results were expressed as the percent-
age of the left side (reconstructed with eSF conduits) to the nonoperated
contralateral side, as a mean of five samples per condition (mean ± SD).
Histological Preparation: Immediately after harvesting, both recon-
structed nerves and healthy contralateral nerves were subjected to in situ
fixation by immersing in 4 vol% paraformaldehyde. Sections 3 mm into
the NGC (after C1X area) were cut longitudinally and further processed
for hematoxylin and eosin (H&E) staining. Briefly, samples were deparaf-
finized in xylol, hydrated through decreasing ethanol series (100%, 96%,
70%, and 50 vol% alcohol) and finally washed in distilled water. After im-
mersion in hematoxylin, samples were rinsed in running soft tap water.
Samples were then immersed in an 80% alcohol solution and briefly in the
eosin staining. Slides were dehydrated through 96 vol% ethanol, absolute
ethanol and finally cleared in xylol and mounted. Longitudinal sections
were analyzed for longitudinal nerve area and assessment of regenerated
nerve cable formation.
Histomorphometric Analysis of Explanted Nerve: Immediately after har-
vesting, both reconstructed nerves and healthy contralateral nerves were
subjected to in situ fixation by immersing in 4 vol% paraformaldehyde.
The nerve was then harvested and processed as previously described.[58]
Briefly, the explant was embedded in epoxy resin and 1 µm thick sections
were obtained and stained with osmium tetroxide followed by 1 vol% tolu-
idine blue. Cross-sections of the proximal nerve (3 mm from the conduit,
PNX) were analyzed for axon count. Image analysis was performed using
ImageJ software.
Statistical Analysis: Numerical data were represented as mean ± SD.
At least three specimens were used in each condition. Statistical analysis
was performed using the GraphPad Prism 5.0 (GraphPad Software, USA)
For ELISA quantification analysis, the experiments were repeated three
independent times (n = 3) and represented as mean ± SD. A Shapiro-
Wilk test was used to ascertain about the data normality. Subsequently, a
Kruskal-Wallis test was performed followed by Dunn’s Multiple compar-
ison test, where the significance level was set to p < 0.05. The biologi-
cal in vitro experiments were repeated three independent times (n = 3)
and represented as mean ± SD. For in vitro statistical analyses, a two-
tailed Mann Whitney test was used (p < 0.05). For the in vivo assay, 15
rats were used, with five specimens for each condition. For in vivo image
analysis, the values represent mean ± SD. A two-tailed Mann Whitney test
was used (p < 0.05). For percentage of muscle weight loss, results were
expressed as the percentage of the left side (reconstructed with eSF con-
duits) to the nonoperated contralateral side, as a mean of five samples per
condition. Subsequently, a Kruskal-Wallis test was performed followed by
Dunn’s Multiple comparison test, where the significance level was set to
p < 0.05.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
Acknowledgements
This work was supported by C.R.C.’s Ph.D. scholarship (Norte-08-5369-
FSE-000037) and awarded FLAD scholarship (Proj. 29/2018). The FCT
distinctions attributed to J.M.O. (IF/00423/2012 and IF/01285/2015) and
J.S.-C. (IF/00115/2015) under the Investigador FCT program are also
greatly acknowledged. The authors also thank Ijaz Ahmed from the BME
department and Joe Steel from NJCBM, both from Rutgers University, for
their important contribution in this scientific paper. The New Jersey Center
for Biomaterials at Rutgers University provided additional support for this
study. The authors acknowledge the project: “Nano-accelerated nerve re-
generation and optogenetic empowering of neuromuscular functionality”
(ref. PTDC/NAN-MAT/29936/2017).
Conflict of Interest
The authors declare no conflict of interest.
Keywords
nerve guidance conduits, neurotrophic factors, peripheral nerve regener-
ation, retrograde transport, silk fibroin
Received: May 4, 2020
Revised: October 15, 2020
Published online:
[1] M. Wiberg, G. Terenghi, Surg. Technol. Int. 2003, 11, 303.
[2] D. Grinsell, C. P. Keating, Biomed. Res. Int. 2014, 2014, 1.
[3] C. R. Carvalho, J. B. Costa, A. da Silva Morais, R. López-Cebral, J.
Silva-Correia, R. L. Reis, J. M. Oliveira, Adv. Healthcare Mater. 2018,
7, 1800186.
[4] R. Deumens, A. Bozkurt, M. F. Meek, M. A. Marcus, E. A. Joosten, J.
Weis, G. A. Brook, Prog. Neurobiol. 2010, 92, 245.
[5] N. Patel, K. Lyon, J. Huang, Neural Regener. Res. 2018, 13, 764.
[6] A. Magaz, A. Faroni, J. E. Gough, A. J. Reid, X. Li, J. J. Blaker, Adv.
Healthcare Mater. 2018, 7, 1800308.
[7] a) S. Das, U. Bora, B. B. Borthakur, in Silk Biomaterials for Tissue Engi-
neering and Regenerative Medicine (Ed: S. C. Kundu), Woodhead Pub-
lishing, Cambridge 2014, p. 41; b) D. Jao, X. Mou, X. Hu, J. Funct.
Biomater. 2016, 7, 22.
[8] P. J. Horner, F. H. Gage, Nature 2000, 407, 963.
[9] P. J. Kingham, G. Terenghi, J. Anat. 2006, 209, 511.
[10] K. Tajdaran, K. Chan, T. Gordon, G. H. Borschel, Exp. Neurol. 2019,
319, 112817.
[11] M. F. Meek, J. H. Coert, Ann. Plast. Surg. 2008, 60, 110.
[12] M. Blais, P. Lévesque, S. Bellenfant, F. Berthod, Tissue Eng., Part A
2013, 19, 1655.
[13] K. M. Rich, J. R. Luszczynski, P. A. Osborne, E. M. Johnson Jr, J. Neu-
rocytol. 1987, 16, 261.
[14] V. Wong, R. Arriaga, N. Y. Ip, R. M. Lindsay, Eur. J. Neurosci. 1993, 5,
466.
[15] A. Blesch, M. H. Tuszynski, J. Comp. Neurol. 2003, 467, 403.
[16] J. C. Petruska, L. M. Mendell, in Encyclopedia of Neuroscience (Ed: L.
R. Squire), Academic Press, Oxford 2009, p. 71
[17] P. R. Ho, G. M. Coan, E. T. Cheng, C. Niell, D. M. Tarn, H. Zhou, D.
Sierra, D. J. Terris, Arch. Otolaryngol., Head Neck Surg. 1998, 124, 761.
[18] S. Tang, J. Zhu, Y. Xu, A. P. Xiang, M. H. Jiang, D. Quan, Biomaterials
2013, 34, 7086.
[19] S. Wang, Q. Cai, J. Hou, J. Bei, T. Zhang, J. Yang, Y. Wan, J. Biomed.
Mater. Res., Part A 2003, 66A, 522.
[20] S. Madduri, M. Papaloïzos, B. Gander, Biomaterials 2010, 31, 2323.
[21] L. Uebersax, M. Mattotti, M. Papaloïzos, H. P. Merkle, B. Gander, L.
Meinel, Biomaterials 2007, 28, 4449.
[22] a) P. D. Chowdary, D. L. Che, K. Zhang, B. Cui, Biophys. J. 2015, 108,
2691; b) K. Ito, H. Enomoto, J. Biochem. 2016, 160, 77.
[23] N. Abe, V. Cavalli, Curr. Opin. Neurobiol. 2008, 18, 276.
[24] U. Paravicini, K. Stoeckel, H. Thoenen, Brain Res. 1975, 84, 279.
[25] G. Rosso, P. Young, V. Shahin, Cell. Physiol. Biochem. 2017, 44,
1263.
[26] G. Corfas, M. O. Velardez, C.-P. Ko, N. Ratner, E. Peles, J. Neurosci.
2004, 24, 9250.
Adv. Healthcare Mater. 2020, 2000753 © 2020 Wiley-VCH GmbH2000753 (13 of 14)
www.advancedsciencenews.com www.advhealthmat.de
[27] F. Liu, H. Lin, C. Zhang, Methods Mol. Biol. 2016, 1453, 33.
[28] C. Liu, C. Wang, Q. Zhao, X. Li, F. Xu, X. Yao, M. Wang, Biomed. Mater.
2018, 13, 044107.
[29] N. Xiao, Q.-T. Le, Arch. Immunol. Ther. Exp. 2016, 64, 89.
[30] B. Wang, J. Yuan, J. Xu, X. Chen, X. Ying, P. Dong, Exp. Ther. Med.
2017, 13, 178.
[31] R. D. Abbott, E. P. Kimmerling, D. M. Cairns, D. L. Kaplan, ACS Appl.
Mater. Interfaces 2016, 8, 21861.
[32] S. Madduri, B. Gander, J. Peripher. Nerv. Syst. 2010, 15, 93.
[33] I. Alfano, P. Vora, R. S. Mummery, B. Mulloy, C. C. Rider, Biochem. J.
2007, 404, 131.
[34] S. Catrina, B. Gander, S. Madduri, Eur. J. Pharm. Biopharm. 2013, 85,
139.
[35] G. Rosso, I. Liashkovich, P. Young, D. Rohr, V. Shahin, Nanomed.:
Nanotechnol., Biol., Med. 2017, 13, 493.
[36] L. N. Novikova, A. Mosahebi, M. Wiberg, G. Terenghi, J. O. Kellerth,
L. N. Novikov, J. Biomed. Mater. Res., Part A 2006, 77A, 242.
[37] a) C. S. Hughes, L. M. Postovit, G. A. Lajoie, Proteomics 2010, 10,
1886; b) S. J. Lee, W. Zhu, L. Heyburn, M. Nowicki, B. Harris, L. G.
Zhang, IEEE Trans. Biomed. Eng. 2017, 64, 408; c) S. Wu, M. S. Chen,
P. Maurel, Y. S. Lee, M. B. Bunge, T. L. Arinzeh, J. Neural Eng. 2018,
15, 056010.
[38] Saijilafu, F.-Q. Zhou, J. Vis. Exp. 2012, 66, 4141.
[39] a) C. Xue, H. Zhu, D. Tan, H. Ren, X. Gu, Y. Zhao, P. Zhang, Z. Sun, Y.
Yang, J. Gu, Y. Gu, X. Gu, J. Tissue Eng. Regener. Med. 2018, 12, e1143;
b) Y. C. Lin, M. Ramadan, M. Hronik-Tupaj, D. L. Kaplan, B. J. Philips,
W. Sivak, J. P. Rubin, K. G. Marra, Ann. Plast. Surg. 2011, 67, 147.
[40] a) D. M. Thompson, H. M. Buettner, Ann. Biomed. Eng. 2006, 34, 161;
b) R. P. Bunge, J. Exp. Biol. 1987, 132, 21.
[41] D. A. Tonge, J. P. Golding, M. Edbladh, M. Kroon, P. E. Ekstrom, A.
Edstrom, Exp. Neurol. 1997, 146, 81.
[42] K. R. Jessen, R. Mirsky, Front. Cell. Neurosci. 2019, 13, 33.
[43] N. Mirzakhani, A. A. Farshid, E. Tamaddonfard, M. Imani, A. Erfan-
parast, F. Noroozinia, Life Sci. 2018, 215, 22.
[44] G. Lundborg, L. Dahlin, D. Dohi, M. Kanje, N. Terada, J. Hand Surg.:
Br. Eur. Vol. 1997, 22, 299.
[45] M. A. Bisby, Fed. Proc. 1982, 41, 2307.
[46] L. S. Zweifel, R. Kuruvilla, D. D. Ginty, Nat. Rev. Neurosci. 2005, 6, 615.
[47] A. B. Ghnenis, R. E. Czaikowski, Z. J. Zhang, J. S. Bushman, J. Vis. Exp.
2018, 137. https://doi.org/10.3791/58031
[48] S. E. MacKinnon, A. L. Dellon, J. P. O’Brien, Muscle Nerve 1991, 14,
1116.
[49] E. C. Novosel, C. Kleinhans, P. J. Kluger, Adv. Drug Delivery Rev. 2011,
63, 300.
[50] P. Sierpinski, J. Garrett, J. Ma, P. Apel, D. Klorig, T. Smith, L. A. Koman,
A. Atala, M. Van Dyke, Biomaterials 2008, 29, 118.
[51] H. K. Wang, Y. X. Wang, C. B. Xue, Z. M. Li, J. Huang, Y. H. Zhao, Y.
M. Yang, X. S. Gu, Neural Regener. Res. 2016, 11, 168.
[52] H. Wang, H. Zhu, Q. Guo, T. Qian, P. Zhang, S. Li, C. Xue, X. Gu,
Front. Cell. Neurosci. 2017, 11, 323.
[53] M. Blais, P. Levesque, S. Bellenfant, F. Berthod, Tissue Eng., Part A
2013, 19, 1655.
[54] L. P. Yan, J. Silva-Correia, V. P. Ribeiro, V. Miranda-Goncalves, C. Cor-
reia, A. da Silva Morais, R. A. Sousa, R. M. Reis, A. L. Oliveira, J. M.
Oliveira, R. L. Reis, Sci. Rep. 2016, 6, 31037.
[55] a) A. P. Balgude, X. Yu, A. Szymanski, R. V. Bellamkonda, Biomate-
rials 2001, 22, 1077; b) J. Bilsland, M. Rigby, L. Young, S. Harper, J.
Neurosci. Methods 1999, 92, 75.
[56] a) C. Deister, C. E. Schmidt, J. Neural Eng. 2006, 3, 172; b) H. B. Wang,
M. E. Mullins, J. M. Cregg, A. Hurtado, M. Oudega, M. T. Trombley,
R. J. Gilbert, J. Neural Eng. 2009, 6, 016001.
[57] S. Wang, A. C. Wan, X. Xu, S. Gao, H. Q. Mao, K. W. Leong, H. Yu,
Biomaterials 2001, 22, 1157.
[58] W. Chang, M. B. Shah, P. Lee, X. Yu, Acta Biomater. 2018, 73, 302.
Adv. Healthcare Mater. 2020, 2000753 © 2020 Wiley-VCH GmbH2000753 (14 of 14)
